Published in Gene Therapy Weekly, February 5th, 2004
The company has in inventory the VEGF-2 plasmid required for its upcoming phase IIb clinical trial.
Richard Otto, CEO of Corautus, commented, "Signing this manufacturing agreement is an important building block as we look beyond our phase IIb trial to plan for phase III trials and projected future commercialization of our product. We have decided to enter into this agreement now because it gives us the assurance that if the timelines for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.